Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk-Reference-Cited by-同舟云学术

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk

Published:2014 Issue:5 Volume:78 Page:1073-1082
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Hirayama Atsushi¹,Honarpour Narimon²,Yoshida Masayuki³,Yamashita Shizuya⁴,Huang Fannie⁵,Wasserman Scott M.²,Teramoto Tamio⁶

Affiliation:

1. Division of Cardiology, Department of Medicine, Nihon University School of Medicine

2. Clinical Development, Amgen Inc

3. Life Science and Bioethics Research Center, Tokyo Medical and Dental University

4. Department of Community Medicine, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

5. Biostatistics, Amgen Inc

6. Teikyo Academic Research Center, Teikyo University

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/78/5/78_CJ-14-0130/_pdf

Reference38 articles.

1. 1. Global Atlas on Cardiovascular Disease Prevention and Control 2011. http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21049&Itemid= (accessed 9 December, 2013).

2. 2. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 2011; 18: 83–88.

3. 3. Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Prev Med 2011; 52: 381–386.

4. 4. Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 2000; 29: 837–844.

5. 5. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TEXCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074–1079.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials;2024-07-11

2. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study;BMC Medical Research Methodology;2024-06-22

3. A Complete Sojourn of Monoclonal Antibodies: AI, Rare Diseases / Disorders and Immunotoxic Effects;Current Proteomics;2024-06

4. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease;Pharmacoepidemiology;2024-03-05

5. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial;The Lancet Regional Health - Western Pacific;2023-12